Breaking News

Statement by Assistant Secretary for Mine Safety and Health Williamson recognizing America’s mine workers on National Miners Day Daily Press Briefing by the Office of the Spokesperson for the Secretary-General Wellesley Island Border Patrol Agents and the Jefferson County Sheriff’s Office Seized Approximately 150 Pounds of Marijuana FEMA Awards Almost $4.5 Million to Manchester-by-the-Sea to Fight Flooding Readout of Deputy Secretary of Defense Dr. Kathleen H. Hicks’ Meeting With U.K. Permanent Under Secretary of Defence David Williams News Release – VIDEO CONSUMER ALERT: Google Voice Identity Theft is On the Rise Remarks by Deputy Secretary of Commerce Don Graves at the NetZero World Industry Summit CSAF promotes retired WWII triple ace fighter pilot to brigadier general > Air Force > Article Display

Issued: London UK

GlaxoSmithKline (GSK) today confirmed that the Federal Patents Court in Munich, Germany, has ruled in patent litigation regarding GSK’s product Viani, an inhaled respiratory treatment for asthma and COPD. The Court ruled in favour of the claimants Mylan dura GmbH, Hexal AG, Neolab Ltd., and IVAX International B.V. in deciding that under German law GSK’s German combination patent for Viani (relating to the combination of the active ingredients salmeterol and fluticasone propionate) was not valid.

The decision relates solely to the German combination patent for Viani and is not binding in any other jurisdiction. GSK also owns a number of other patents in Germany relevant to Viani including the Diskus dry powder inhaler and HFA aerosol formulation patents which expire in 2011 and 2012 respectively. In addition, there are significant technical hurdles and complexities associated with the introduction of inhaled respiratory products. GSK is studying the judgment and will be considering an appeal to a higher court.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

   

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

   

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

 

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jen Hill Baxter

(215) 751 7002

Source link